


GARFIELD-VTE

Taking a real-world deep dive into VTE

ABOUT VTE

Venous thromboembolism (VTE) is the formation of **blood clots in the vein**.

- Pulmonary embolism (**PE**) is a clot in the lungs
- Deep vein thrombosis (**DVT**) is a clot in a deep vein (usually in the leg)



3rd 

Most common cardiovascular illness, after acute coronary syndrome and stroke.¹

37 

VTE kills one person every 37 seconds in the Western world.²

2x 

In Europe, the annual death rate from VTE is more than twice that of AIDS, breast cancer, prostate cancer and traffic accidents combined per year.³

90% 

Fatal cases of VTE that are undetected or untreatable prior to death.⁴

780K 

Deaths in Europe and the US each year.²

£640M 

The amount the UK NHS spends per year on VTE treatment and management.⁵



The risk of **recurrent VTE** is high, especially in the **first 6 – 12 months** after anticoagulant therapy stops.⁶

Another serious long-term VTE complication is post-thrombotic syndrome (PTS):

- PTS is the most common complication (**20 – 50% within 2 years of first DVT**) and is severe in 10 – 15% of cases
- PTS costs billions of pounds per year in time lost from work and in medical expenses and **leads to disability and reduced quality of life**.



ABOUT THE REGISTRY

Study start:
July 2014

Recruitment closed:
September 2016

Study end:
April 2020

The Breakdown:



2
sequential cohorts



28
countries



415
sites



10,879
newly diagnosed VTE patients

Emerging Registry Insights:



Death is the **No. 1 major adverse outcome** in VTE patients – 50% are cancer-related.



Anticoagulant **treatment patterns for VTE vary** by patient population, region and DVT site.



Most VTE patients with cancer are **treated with LMWH*** (as per guidelines), while DOACs* are prescribed to 25% of patients.



VTE patients vary widely and **need personalised therapy**.



References

1. What is Venous Thromboembolism (VTE)? American Heart Association, http://www.heart.org/HEARTORG/Conditions/More/What-is-Venous-Thromboembolism-VTE_UCM_479052_Article.jsp#. WvymR4Tytg [Accessed July 2017 t3 Aug 2016]. //2. GARFIELD-VTE Registry. About VTE. Available at <http://vte.garfieldregistry.org/about/about-vte> [Accessed: 5 July 2017] //3. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe, Thromb Haemost. 2007; 98: 756-764 //4. GARFIELD-VTE Registry. About VTE. Available at <http://vte.garfieldregistry.org/about/about-vte> [Accessed: 5 June 2017] //5. Wirral University Teaching Hospital NHS Foundation Trust. Venous Thromboembolism in Adults (- The Prevention and Management of). Available at <http://www.wuth.nhs.uk/media/391153/199-Venous-Thromboembolism-in-Adults-The-Prevention-Management-of-2013-07-v94.pdf> [Accessed: 6 July 2017] //6. Gualtiero Palareti. Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It, Scientifica vol. 2012, Article ID 391734, 17 pages, 2012. doi:10.6064/2012/391734 // * LMWH - Low Molecular Weight Heparin, * DOAC - Direct Oral Anticoagulants

For more information, visit www.garfieldregistry.org

The GARFIELD-VTE registry is an independent academic research initiative sponsored by the Thrombosis Research Institute (London, UK) and supported by an unrestricted research grant from Bayer AG (Berlin, Germany).